Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[Lu-177]-Catalase in advanced malignant neoplasms
NCT05985278Phase 1Recruiting
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Jul 2023
- Primary completion
- Jun 2026
- Modality
- Hydrogel Systems, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of lutetium-177-catalase in advanced malignant solid tumor, sponsored by Peking University Cancer Hospital & Institute. Primary endpoint: The absorbed radiation dose of tumor and normal organs at 8 weeks. Started Jul 2023; status: recruiting.
02
Drugs
lutetium-177-catalase
03
Conditions
advanced malignant solid tumor
Beyond the preview
Go deeper on NCT05985278.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05985278.